secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001104659-22-086131
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q2 net loss $41M; rusfertide Phase 3 enrollment slower, cash runway to end 2024
--------------------------------------------------------------------------------

- Net loss of $41.0M ($0.84 per share) vs $30.8M loss in Q2 2021; license revenue $0.9M.
- Cash and equivalents $291.9M, expected to fund operations through end of 2024.
- Phase 3 VERIFY study enrollment slower than anticipated; target to complete enrollment by end of first half 2023.
- Janssen (PN-235) advancing Phase 2b psoriasis studies; $10M milestone for second indication Phase 2 start, $50M for Phase 3 dosing.
- PN-943 seeking FDA guidance for Phase 3 and partnership; IDEAL study results to be presented at UEGW Oct 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922086131/0001104659-22-086131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922086131/tm2222452d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-086131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer